In Africa, GlaxoSmithKline (GSK) are faced with the reality of the AIDS crisis every day, and its decisions impact thousands. There were no easy answers to the crisis, but all - governments, NGOs, the media, shareholders, and others - had an opinion. GSK was to determine how to address the crisis while maintaining the viability of the business in developing countries, including all the pressures. Throughout the late 1990s, General Director of GSK, Stanford Graduate School of Business graduate, Dr Jean-Pierre Garnier, has been at the forefront of debates antiretroviral drug prices, patent protection and access to medicines. Proactive in dealing with critics, he was seen as the de facto representative of the pharmaceutical industry in addressing these important issues. He responded to criticism of speaking at every opportunity, including writing two letters to the editor of Financial Times to clarify the position in the industry of medicine prices, research and development, and access to medicines. These messages set the tone for the company and its activities around the world. "Hide
by David P. Baron, Soon Jin Lim, Deborah Liu Source: Stanford Graduate School of Business 14 pages. Publication Date: August 7, 2003. Prod. #: P39-PDF-ENG
Related Case Solutions & Analyses:
Solutions For Customer Complaints About Offshoring And Outsourcing Services
Investment Technology Group
Operational Capabilities: Hidden in Plain View
Retail Relay A
Future of Hybrid Electric Vehicles
Liquid Gold: Calambra Olive Oil (A)
Publishing Group of America (B)
Drugstore.com
Charles Schwab Corp. (A)
Strategic Countermoves: Coca-Cola vs. Pepsi, Spanish Version
